Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meropenem + xeruborbactam
- Development stage
- Unknown
- Lead developer
- Qpex Biopharma
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**Meropenem + xeruborbactam** is an investigational, intravenously administered antibacterial combination consisting of the carbapenem antibiotic meropenem and xeruborbactam (formerly QPX7728), an ultra-broad-spectrum bicyclic boronate beta-lactamase inhibitor. Developed by Qpex Biopharma (acquired by Shionogi), this combination is designed to treat serious Gram-negative bacterial infections, particularly those caused by carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant *Acinetobacter baumannii* (CRAB). Xeruborbactam potently inhibits serine and metallo-beta-lactamases (Ambler Classes A, B, C, and D), including KPC, NDM, VIM, IMP, and OXA-type enzymes, thereby protecting meropenem from enzymatic degradation and restoring its bactericidal activity. Additionally, xeruborbactam exhibits modest intrinsic antibacterial activity against Enterobacterales by binding to penicillin-binding proteins (primarily PBP3). The combination has completed Phase 1 clinical evaluation in healthy volunteers.
- Other names
- MEM-XERMEM-XERUmeropenem + QPX7728meropenem-xeruborbactammeropenem/xeruborbactamQPX7728 + meropenem
02
Targets
Class A BL (Class A beta-lactamase)AmpC (AmpC beta-lactamase)PBP2 (Penicillin-binding protein 2)PBP3 (Peptidoglycan D,D-transpeptidase FtsI)MBL (Class B metallo-beta-lactamase)OXA (Class D beta-lactamase)
Beyond the preview
Go deeper on meropenem + xeruborbactam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meropenem + xeruborbactam.